Webinar Alert! Assessing the Use of Non-Human Primates in Translational Research Today Register Today!

Integrated Preclinical Safety and Efficacy Programs for Allogeneic ‘Off-the-Shelf’ CAR-T Cell Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Integrated Preclinical Safety and Efficacy Programs for Allogeneic ‘Off-the-Shelf’ CAR-T Cell Therapies

CELL & GENE | RNA | BIOLOGICS

We outline the strategic framework for designing and executing integrated preclinical programs for allogeneic CAR-T cell therapies. We detail the necessary in vivo safety and efficacy studies, bioanalytical assays, and GxP-compliant data generation required for a successful Investigational New Drug (IND) application. The focus is on addressing the unique biological challenges of ‘off-the-shelf’ constructs, including potential for Graft-versus-Host Disease (GvHD), host rejection, and Cytokine Release Syndrome (CRS).

Technical Question Franklin Biolabs’ Approach
How do you model CRS and ICANS for allogeneic CAR-T in preclinical studies? We utilize humanized immune system models that are specifically designed to recapitulate key aspects of the human cytokine response. Serial blood sampling and multiplex cytokine analysis (e.g., Luminex) are integrated into efficacy and toxicology studies to monitor for CRS-associated biomarkers and establish a safe therapeutic window.
What is the standard approach for assessing GvHD risk with ‘off-the-shelf’ products? GvHD assessment is a primary safety endpoint. We employ immunocompromised models reconstituted with human peripheral blood mononuclear cells (PBMCs) and monitor for clinical signs of GvHD, including weight loss, skin changes, and other systemic indicators. This is supported by comprehensive Histology on all relevant tissues.
How are persistence and rejection kinetics evaluated for non-autologous CAR-T cells? We use a multi-modal strategy combining quantitative PCR (qPCR) or droplet digital PCR (ddPCR) to quantify CAR transgene levels in blood and tissues over time. This is correlated with flow cytometry to assess the phenotype and frequency of CAR-T cells, providing a clear picture of cell engraftment, expansion, and eventual clearance by the host immune system.
What are the key considerations for non-target tissue biodistribution studies? For CAR-T, these studies are designed to confirm the localization of therapeutic cells to the tumor microenvironment and lymphoid tissues while assessing any undesirable accumulation in other organs. We use sensitive qPCR-based methods on a comprehensive set of tissues collected at multiple time points post-administration to build a complete distribution profile.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Program Architecture for IND Success

An effective preclinical program for allogeneic CAR-T requires a purpose-built strategy that moves beyond standard toxicology designs. The objective is to generate a cohesive data package that directly addresses the questions regulators will ask about safety, activity, and cell fate. This involves a phased approach that integrates efficacy, biodistribution, and safety endpoints into well-controlled in vivo studies.

Our programs are designed to characterize the therapeutic product’s behavior from initial administration through clearance, providing a clear rationale for the proposed clinical starting dose and escalation scheme.

De-risking Complex Allogeneic Biology

The primary challenges for ‘off-the-shelf’ CAR-T therapies involve the complex interactions between the therapeutic cells, the host immune system, and the tumor. Our study designs are built to proactively investigate these phenomena.

Key study components include:

  • In Vivo Efficacy: Evaluation of anti-tumor activity in relevant xenograft models to establish dose-dependent efficacy and provide a basis for therapeutic index calculations.

  • Pharmacokinetics and Persistence: Quantitative assessment of CAR-T cell expansion, contraction, and persistence kinetics to understand the duration of therapeutic activity and potential for long-term toxicity.

  • Safety and Toxicology: Comprehensive GxP-compliant studies to identify potential toxicities, including CRS, GvHD, and on-target, off-tumor effects. This includes daily clinical observations, clinical pathology, and terminal Histology.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Translational Modeling and Strategic Insights

Developing a robust safety profile requires data from multiple, translationally relevant systems. The strategic value of this cross-species approach was highlighted in AAV gene therapy development, where data from different models helped establish a favorable safety profile for a novel construct prior to clinical entry (PMID: 35333110). We apply this same principle to cell therapies, using carefully selected in vivo models to understand potential liabilities before they can impact human trials. Our >100,000 sq ft facility is equipped to enable these complex, multi-arm studies.

Animal Welfare and GxP Compliance

Franklin Biolabs is fully committed to the highest standards of animal welfare and ethical research conduct.

To review our complete commitment to responsible research, .

Our animal care and use program is designed to meet the highest ethical standards, strictly adhering to the 3Rs principles (Reduce, Refine, Replace). All IND-enabling studies are performed within a rigorous GxP framework, ensuring data integrity and regulatory acceptance. This disciplined approach has supported an average 18-24 month IND timeline for our clients and has contributed to a 100% IND success rate for programs initiated since 2019. Franklin Biolabs as a brand launched in 2024, building on this established operational history.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities